Ascentage Pharma Announces Series B Financing of RMB 500 Million

Medicilon has been recognized as one of the top drug discovery contract research organizations (CRO) in China and is managed by a team of scientists with a wealth of experience in US-based pharmaceutical and biotechnology companies. As our areas of expertise and service capabilities continue to expand, more and more pharmaceutical and biotechnology companies have taken advantage of our integrated drug discovery and development services.Email:marketing@medicilon.com.cn Web:www.medicilon.com

On December 22, 2016, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) approval to APG-1252, a novel Bcl-2/Bcl-x L inhibitor which is discovered and developed by Ascentage, for the treatment of cancers including Small Cell Lung Cancer (SCLC). APG-1252 is a small molecule drug that helps restore programmed cell death process (apoptosis) through selective inhibition of Bcl-2 family members Bcl-2 and Bcl-x L . Rationally designed to avoid the commonly seen on-target toxicity in platelets when Bcl-x L gets inhibited, APG-1252 is of best-in-class potential. The pre-clinical data shows that the compound remains strong anti-tumor potency while exhibiting minimal toxicity in platelets.

The proceeds of financing will provide strong support for Ascentage to further accelerate its pipeline of novel small molecules that target apoptosis pathways in clinical development. Protein-Protein Interactions (PPIs) have long been known by their vital importance in regulating biological systems and development of disease states. Using small molecule drugs to directly disrupt PPIs is relatively rare in comparison to other drug classes due to the complexity and challenge in drug design. Ascentage team has been committed to this cutting-edge field for the past years with a vision of conquering the "undruggable" targets. The research efforts and valuable insight on these targets have been translated into a rich pipeline of eight novel small molecules with six currently in clinical development for addressing the unmet medical needs in oncology and hepatitis B. Furthermore, Ascentage is partnering with UNITY Biotechnology, a San Francisco-based biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, on developing ground-breaking senolytic treatments for age-related diseases. This collaboration will further enhance the therapeutic potential of Ascentage's compounds.

Simon Dazhong Lu, Managing Director of SDIC Fund Management, commented on the financing round: "We are highly attracted by Ascentage's unique technology platform and strong capabilities in novel drug development. We hope that Ascentage will soon deliver breakthrough therapeutics for patients worldwide."

Dajun Yang, MD, Ph.D., Co-founder, Chairman and Chief Executive Officer of Ascentage, said: "we are pleased by the overwhelming interest that we received in this round of financing led by SDIC. We believe that this is an endorsement of our PPIs-targeting technology, our novel apoptosis-inducing therapies, as well as our vision of building a world-leading biopharmaceutical company. The capital raised will be invaluable in enabling us to progress the clinical development of our pipeline especially in the United States and to accelerate our manufacturing site construction in Suzhou. We look forward to working closely with all our investors to continue the rapid advancement of developing novel drugs."

About Ascentage Pharma

Ascentage Pharma is a global, clinical-stage biopharmaceutical company, dedicated to discovery and development of "first-in-class" and "best-in-class" small-molecule targeted therapeutics for addressing unmet medical needs in cancers, hepatitis B and age-related diseases. Ascentage has world-leading proprietary Protein-Protein Interaction drug discovery technologies and holds over 80 international patents. Ascentage currently has six small molecule drugs in phase I-II trials in US, Australia and China and additional programs in preclinical stages.

The established R&D pipeline of Ascentage includes the inhibitors to a number of key proteins, including IAP, Bcl-2/Bcl-xL and MDM2-p53, that regulate a tumor cell's programmed cell death program; 2nd and/or 3rd generation of kinase inhibitors that overcome mutant resistance in cancer therapy; and inhibitors of epigenetics.